Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277291 | 0.99 | EPHX2 (0.47) | EPHX2CPB2SMN1; SMN2C3AR1NMT2 | |
| SCHEMBL6561158 | 0.82 | GRIN1 (0.44) | EPHX2SMN1; SMN2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL30417895 | 0.81 | CPB2 (0.48) | EPHX2CPB2SMN1; SMN2 | |
| SCHEMBL8071216 | 0.81 | EPHX2 (0.39) | EPHX2CPB2SMN1; SMN2C3AR1GNPAT | |
| SCHEMBL7897054 | 0.81 | EPHX2 (0.44) | EPHX2CPB2SMN1; SMN2C3AR1CHRNB2 | |
| SCHEMBL17104387 | 0.81 | GRIN1 (0.45) | EPHX2CPB2SMN1; SMN2CHRNB2CHRNB4 | |
| SCHEMBL6562711 | 0.81 | GRIN1 (0.45) | EPHX2CPB2SMN1; SMN2CHRNB2CHRNB4 | |
| SCHEMBL17771353 | 0.80 | CPB2 (0.57) | CPB2NMT2NMT1 | |
| SCHEMBL24961322 | 0.79 | GNPAT (0.45) | EPHX2C3AR1GNPAT | |
| SCHEMBL4647818 | 0.79 | C3AR1 (0.45) | EPHX2C3AR1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632171-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-9458201-B2 | Melanocortin receptor-specific heptapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20140357575-A1 | Melanocortin Receptor-Specific Heptapeptides | PALATIN TECHNOLOGIES INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8846601-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120178701-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357575-A1 | Melanocortin Receptor-Specific Heptapeptides | MC5R, MC1R, MC3R | EPHX2 2596/4885CPB2 466/4885SMN1; SMN2 1225/4885 |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC4R | EPHX2 3711/4885CPB2 1064/4885SMN1; SMN2 1059/4885 |
| US-10632171-B2 | Melanocortin receptor-specific peptides | MC1R, MC3R, MC4R | EPHX2 3711/4885CPB2 1064/4885SMN1; SMN2 1059/4885 |
| US-20120178701-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC5R | EPHX2 3627/4885CPB2 1299/4885SMN1; SMN2 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.